Advertisement

Pseudomonas aeruginosa

  • David L. Paterson
  • Baek-Nam Kim
Part of the Infectious Disease book series (ID)

P. aeruginosa is a Gram-negative bacillus that is typically 1–3 µm in length. The organism is typically a strict aerobe. It grows on many solid media and can grow at both 37 and 42°. Most strains have a characteristic grapelike odor. It does not ferment carbohydrates. It is positive in the indophenol oxidase test, and is Simmon’s citrate positive, l-arginine dehydrolase positive, l-lysine decarboxylase negative, and l-ornithine decarboxylase negative (1).

Keywords

Pseudomonas Aeruginosa Bloodstream Infection Antimicrob Agent Otitis Externa Ecthyma Gangrenosum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA and Yolken RH, eds. Manual of Clinical Microbiology, 8th ed, Vol. 1. Washington, DC: American Society for Microbiology Press, 2003:719–728Google Scholar
  2. 2.
    Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43 Suppl 2:S43–S48PubMedCrossRefGoogle Scholar
  3. 3.
    Morrison AJ, Jr, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984;6 Suppl 3: S627–S642PubMedGoogle Scholar
  4. 4.
    Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bron-choscopes. N Engl J Med 2003;348:221–227PubMedCrossRefGoogle Scholar
  5. 5.
    Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867–903PubMedGoogle Scholar
  6. 6.
    Chastre J, Luyt CE, Combes A and Trouillet JL. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin Infect Dis 2006;43 Suppl 2:S75–S81PubMedCrossRefGoogle Scholar
  7. 7.
    Micek ST, Kollef KE, Reichley RM, Roubinian N and Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568–3573PubMedCrossRefGoogle Scholar
  8. 8.
    Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247–250PubMedCrossRefGoogle Scholar
  9. 9.
    Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43 Suppl 2:S49–56PubMedCrossRefGoogle Scholar
  10. 10.
    Lister PD, Gardner VM and Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalospori-nase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999;43:882–889PubMedGoogle Scholar
  11. 11.
    Doi Y, de Oliveira Garcia D, Adams J and Paterson DL. Coproduction of novel 16S rRNA methylase RmtD and metallo- beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother 2007;51:852–856PubMedCrossRefGoogle Scholar
  12. 12.
    Lolans K, Queenan AM, Bush K, Sahud A and Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005;49:3538–3540PubMedCrossRefGoogle Scholar
  13. 13.
    Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazi-dime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991–1996PubMedGoogle Scholar
  14. 14.
    Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K and Quinn J. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 2006;50:3485–3487PubMedCrossRefGoogle Scholar
  15. 15.
    Queenan AM, Torres-Viera C, Gold HS, et al. SME-type carbap-enem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;44:3035–3039PubMedCrossRefGoogle Scholar
  16. 16.
    Quinn JP, Miyashiro D, Sahm D, Flamm R and Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989;33:1451–1456PubMedGoogle Scholar
  17. 17.
    Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA and Bush K. Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother 1993;37:1989–1992PubMedGoogle Scholar
  18. 18.
    Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517–523PubMedCrossRefGoogle Scholar
  19. 19.
    Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135–146PubMedCrossRefGoogle Scholar
  20. 20.
    Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA and Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007;51:1553–1555PubMedCrossRefGoogle Scholar
  21. 21.
    Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657–686PubMedCrossRefGoogle Scholar
  22. 22.
    Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634–640PubMedCrossRefGoogle Scholar
  23. 23.
    Ochs MM, McCusker MP, Bains M and Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999;43:1085–1090PubMedGoogle Scholar
  24. 24.
    Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007;45:88–94PubMedCrossRefGoogle Scholar
  25. 25.
    Doi Y, Ghilardi AC, Adams J, de Oliveira Garcia D and Paterson DL. High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil. Antimicrob Agents Chemother 2007;51:3388–3390PubMedCrossRefGoogle Scholar
  26. 26.
    Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007;45:1179–1181PubMedCrossRefGoogle Scholar
  27. 27.
    Paterson DL, Lipman J. Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med 2007;35:1789–1791PubMedCrossRefGoogle Scholar
  28. 28.
    Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994;38:547–557PubMedGoogle Scholar
  29. 29.
    Carmeli Y, Troillet N, Eliopoulos GM and Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379–1382PubMedGoogle Scholar
  30. 30.
    Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilm-icin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309–1313PubMedGoogle Scholar
  31. 31.
    Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem—cilastatin and piperacillin—tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966–2972PubMedGoogle Scholar
  32. 32.
    Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem— cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442–3447PubMedCrossRefGoogle Scholar
  33. 33.
    Defez C, Fabbro-Peray P, Bouziges N, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004;57:209–216PubMedCrossRefGoogle Scholar
  34. 34.
    Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL and Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005;49:3663–3667PubMedCrossRefGoogle Scholar
  35. 35.
    Bratu S, Quale J, Cebular S, Heddurshetti R and Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005;24:196–201PubMedCrossRefGoogle Scholar
  36. 36.
    Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multid-rug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670–677PubMedCrossRefGoogle Scholar
  37. 37.
    Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002;8:220–221PubMedCrossRefGoogle Scholar
  38. 38.
    Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M and Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128–1133PubMedCrossRefGoogle Scholar
  39. 39.
    Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapen-em-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004;42:5094–5101PubMedCrossRefGoogle Scholar
  40. 40.
    Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapen-emase in Greece. J Clin Microbiol 2000;38:1290–1292PubMedGoogle Scholar
  41. 41.
    Deplano A, Denis O, Poirel L, et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aerugi-nosa. J Clin Microbiol 2005;43:1198–1204PubMedCrossRefGoogle Scholar
  42. 42.
    Hsieh MH, Yu CM, Yu VL and Chow JW. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 1993;16:343–349PubMedCrossRefGoogle Scholar
  43. 43.
    Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA and Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540–546PubMedCrossRefGoogle Scholar
  44. 44.
    Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127–1133PubMedGoogle Scholar
  45. 45.
    Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996;156:2121–2126PubMedCrossRefGoogle Scholar
  46. 46.
    Paul M, Benuri-Silbiger I, Soares-Weiser K and Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328:668PubMedCrossRefGoogle Scholar
  47. 47.
    Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005;5:192–193; discussion 193–194PubMedCrossRefGoogle Scholar
  48. 48.
    Mizuta M, Linkin DR, Nachamkin I, et al. Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a combination antibiogram. Infect Control Hosp Epidemiol 2006;27:413–415PubMedCrossRefGoogle Scholar
  49. 49.
    Bhat S, Fujitani S, Potoski BA, et al. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents 2007;30:458–462PubMedCrossRefGoogle Scholar
  50. 50.
    Lodise TP, Jr, Lomaestro B and Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357–363PubMedCrossRefGoogle Scholar
  51. 51.
    Lorente L, Lorenzo L, Martin MM, Jimenez A and Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219–223PubMedCrossRefGoogle Scholar
  52. 52.
    Bhat SV, Peleg AY, Lodise TP, Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007;51:4390–4395PubMedCrossRefGoogle Scholar
  53. 53.
    Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004;24:803–807PubMedCrossRefGoogle Scholar
  54. 54.
    Li C, Du X, Kuti JL and Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51:1725–1730PubMedCrossRefGoogle Scholar
  55. 55.
    Yang JC, Tsuji BT and Forrest A. Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med 2007;28:586–595PubMedCrossRefGoogle Scholar
  56. 56.
    Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007;28:596–603PubMedCrossRefGoogle Scholar
  57. 57.
    Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589–601PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • David L. Paterson
    • 1
  • Baek-Nam Kim
  1. 1.Centre for Clinical Research, Royal Brisbane and Women's HospitalUniversity of QueenslandBrisbaneAustralia

Personalised recommendations